Actinomycetes: a yet inexhaustive source of bioactive secondary metabolites (original) (raw)

Abstract

The rapid emergence of antimicrobial resistance among pathogens has led to a renewed interest to search for novel antimicrobial agents. The history of new drug discovery processes shows that novel skeletons have, in the majority of cases come from natural sources. This involves screening of microorganisms or plant extracts. They have been the source of, or inspiration for the development of chemical entities introduced as pharmaceutical. Among microorganisms, actinomycetes are enthralling resource due to their ability to produce novel bioactive secondary metabolites with antimicrobial activities. They have proven to be an inexhaustive mine of antimicrobial agents, especially those potent against pathogenic organisms. Microbial secondary metabolites, especially those from actinomycetes have been a phenomenal success for the discovery of novel drugs. They produce a wide range of secondary metabolites and more than 70% of the naturally derived antibiotics are currently in clinical use. They remain a fundamental source of new chemical diversity and an important part of drug discovery. Their ingenuity and immense industrial value is extremely noteworthy. The discovery of Streptomycin from actinomycetes has been imperative to the exploration of this group as a source of novel bioactive compounds. This group of organisms have produce antibiotics in different classes such as aminoglycosides, ansamycins, anthracyclines, glycopeptides, β-lactams, macrolides, nucleosides, peptides, polyenes, polyethers, and tetracyclines. Existence of actinomycetes has been reported in both terrestrial and marine habitats. This chapter highlight the bioactive metabolites produces by actinomycetes and their mode of action.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (65)

  1. Chin Y, Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. American Association of Pharmaceutical Scientists Journal. 2006;8:E239-E253.
  2. Ganesan A. The impact of natural products upon drug discovery. Current Opinion in Chemical Biology. 2008;12:306-317.
  3. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal of Natural Products. 2012;75:311-335.
  4. Berdy J. Bioactive microbial metabolites. Journal of Antibiotics. 2005;58:1-26.
  5. Baltz RH. Antimicrobials from actinomycetes. Back to the future. Microbe 2007;2:125-131.
  6. Naine J, Srinivasan MV, Devi SC. Novel anticancer compounds from marine actinomycetes: A review. Journal of Pharmarcy Research. 2011;4:1285-1287.
  7. Raja A, Prabakarana P. Actinomycetes and drug-an overview. Science Alert. 2011;1:72-84.
  8. Adegboye MF, Babalola OO. Taxonomy and ecology of antibiotic producing actinomycetes. African Journal of Agricultural Research. 2012;7:2255-2261.
  9. Dietz A, Currie S, Jennie CH-C, Angela B. Chapter 5 -actinomycetes. Maintaining cultures for biotechnology and industry. San Diego: Academic Press; 1996. p. 85-99.
  10. Marinelli F, Marcone GL, Microbial secondary metabolites. Comprehensive biotechnology (second edition). Burlington, American: Academic Press; 2011. p. 285-297.
  11. Barrios-González J, Mejýa A. Production of antibiotics and other commercially valuable secondary metabolites. Current developments in solid-state fermentation. Heidelberg, New York: Springer; 2008. p. 302-336.
  12. Sanchez S, Demain AL. Metabolic regulation of fermentation processes. Enzyme and Microbial Technology. 2002;31:895-906.
  13. Vaishnav P, Demain AL. Unexpected applications of secondary metabolites. Biotechnology Advances. 2010;29:223-229.
  14. Donadio S, Monciardini P, Sosio M. Polyketide synthases and nonribosomal peptide synthetases: The emerging view from bacterial genomics. Natural Product Reports. 2007;24:1073-1109.
  15. Ichikawa N, Sasagawa M, Yamamoto M, Komaki H, et al. Dobiscuit: A database of secondary metabolite biosynthetic gene clusters. Nucleic Acids Research. 2013;41:D408-D414.
  16. Arias AA, Craig M, Fickers P. Science against microbial pathogens: Communicating current research and technological advances. In: Méndez Vilas A, editor. Gram-positive antibiotic biosynthetic clusters: a review. Badajoz, Spain: Formatex Research Center; 2011. p. 977-986.
  17. Osbourn A. Secondary metabolic gene clusters: Evolutionary toolkits for chemical innovation. Trends in Genetics. 2010;26:449-457.
  18. Baltz RH. Renaissance in antibacterial discovery from actinomycetes. Current Opinion in Pharmacology. 2008;8:557-563.
  19. Demain AL. Antibiotics: Natural products essential to human health. Medicinal Research Reviews. 2009;29:821-842.
  20. McDermott W, Muschenheim C, Hadley SJ, Bunn PA, et al. Streptomycin in the treatment of tuberculosis in humans. Annals of Internal Medicine. 1947;27:769-822.
  21. Baltz RH. Daptomycin: Mechanisms of action and resistance, and biosynthetic engineering. Current Opinion in Chemical Biology. 2009;13:144-151.
  22. McArthur KA, Mitchell SS, Tsueng G, Rheingold A, et al. Lynamicins a-e, chlorinated bisindole pyrrole antibiotics from a novel marine actinomycete. Journal of Natural Products. 2008;71:1732-1737.
  23. Hughes CC, Prieto-Davo A, Jensen PR, Fenical W. The marinopyrroles, antibiotics of an unprecedented structure class from a marine streptomyces sp. Organic Letters. 2008;10:629-631.
  24. Foster BJ, Clagett-Carr K, Shoemaker DD, Suffness M, et al. Echinomycin: The first bifunctional intercalating agent in clinical trials. Investigational New Drugs. 1985;3:403-410.
  25. Kong D, Park EJ, Stephen AG, Calvani M, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA- binding activity. Cancer Research. 2005;65:9047-9055.
  26. Wang J, Soisson SM, Young K, Shoop W, et al. Platensimycin is a selective fabf inhibitor with potent antibiotic properties. Nature. 2006;441:358-361.
  27. Singh SB, Jayasuriya H, Ondeyka JG, Herath KB, et al. Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. Journal of the American Chemical Society. 2006;128:11916-11920.
  28. McAlpine JB, Banskota AH, Charan RD, Schlingmann G, et al. Biosynthesis of diazepinomicin/eco-4601, a Micromonospora secondary metabolite with a novel ring system. Journal of Natural Products. 2008;71:1585-1590.
  29. Abdelmohsen UR, Szesny M, Othman EM, Schirmeister T, et al. Antioxidant and anti-protease activities of diazepinomicin from the sponge-associated Micromonospora strain rv115. Marine Drugs. 2012;10:2208-2221.
  30. Bonfiglio G, Furneri PM. Novel streptogramin antibiotics. Expert Opinion on Investigational Drugs. 2001;10:185-198.
  31. Kirst HA. The spinosyn family of insecticides: Realizing the potential of natural products research. Journal of Antibiotics. 2010;63:101-111.
  32. Elander R. Industrial production of β-lactam antibiotics. Applied Microbiology and Biotechnology. 2003;61:385-392.
  33. Thykaer J, Nielsen J. Metabolic engineering of β-lactam production. Metabolic Engineering. 2003;5:56-69.
  34. Van Bambeke F, Glupczynski Y, Tulkens PM. Mechanisms of action. Infectious Diseases. 2010;7:128-135.
  35. Anderson RJ, Groundwater PW, Todd A, Worsley AJ. Β-lactam antibiotics. Antibacterial agents. Chichester, UK.: John Wiley and Sons, Ltd; 2012. p. 261-303.
  36. O'Driscoll M, Greenhalgh K, Young A, Turos E, et al. Studies on the antifungal properties of n-thiolated β-lactams. Bioorganic and Medicinal Chemistry. 2008;16:7832-7837.
  37. Busscher GF, Rutjes F, Van Delft FL. 2-deoxystreptamine: Central scaffold of aminoglycoside antibiotics. Chemical Reviews- Columbus. 2005;105:775-792.
  38. Tsai A, Uemura S, Johansson M, Puglisi Elisabetta V, et al. The impact of aminoglycosides on the dynamics of translation elongation. Cell Reports. 2013;3:497-508.
  39. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clinical Microbiology Reviews. 2003;16:430-450.
  40. Hermann T. Aminoglycoside antibiotics: Old drugs and new therapeutic approaches. Cellular and MolecularLife Sciences. 2007;64:1841-1852.
  41. Yang G, Trylska J, Tor Y, McCammon JA. Binding of aminoglycosidic antibiotics to the oligonucleotide a-site model and 30s ribosomal subunit: Poisson-boltzmann model, thermal denaturation, and fluorescence studies. Journal of Medicinal Chemistry. 2006;49:5478-5490.
  42. Finch RG, Greenwood D, Whitley RJ, Norrby SR. Antibiotic and chemotherapy e-book. Philadelphia, American: Saunders; 2010.
  43. Jeya M, Moon H-J, Lee K-M, Kim I-W, et al. Glycopeptide antibiotics and their novel semi-synthetic derivatives. Current Pharmaceutical Biotechnology. 2011;12:1194-1204.
  44. Donadio S, Sosio M. Glycopeptides, antimicrobial. In: Moselio S, editor. Encyclopedia of microbiology (third edition). Oxford, UK: Academic Press; 2009. p. 455-471.
  45. Wohlleben W, Stegmann E, Süssmuth RD. Molecular genetic approaches to analyze glycopeptide biosynthesis. Methods in Enzymology. 2009;458:459-486.
  46. Donadio S, Sosio M. Biosynthesis of glycopeptides: Prospects for improved antibacterials. Current Topics in Medicinal Chemistry. 2008;8:654-666.
  47. Minotti G, Menna P, Salvatorelli E, Cairo G, et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews. 2004;56:185-229.
  48. Abdelfattah MS. Screening of terrestrial streptomyces leading to identification of new stereoisomeric anthracyclines. World Journal of Microbiology and Biotechnology. 2008;24:2619-2625.
  49. Nepomuceno JC. Antioxidants in cancer treatment. InTech. 2011:623-650.
  50. Kizek R, Adam V, Hrabeta J, Eckschlager T, et al. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacology and Therapeutics. 2012;133:26-39.
  51. Lynch A, Harvey J, Aylott M, Nicholas E, et al. Investigations into the concept of a threshold for topoisomerase inhibitor induced clastogenicity. Mutagenesis. 2003;18:345-353.
  52. Nobili S, Lippi D, Witort E, Donnini M, et al. Natural compounds for cancer treatment and prevention. Pharmacological Research. 2009;59:365-378.
  53. Muindi JR, Sinha BK, Gianni L, Myers CE. Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Letters. 1984;172:226-230.
  54. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F. Antibacterial macrolides: A drug class with a complex pharmacological profile. Pharmacological Research. 2004;50:211-222.
  55. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clinical Microbiology Reviews. 2010;23:590-615.
  56. Zuckerman JM. Macrolides and ketolides: Azithromycin, clarithromycin, telithromycin. Infectious Disease Clinics of North America. 2004;18:621-638.
  57. Griffin JH, Pace JL. Multivalent macrolide antibiotics. Google Patents; 2007.
  58. Hansen JL, Moore PB, Steitz TA. Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. Journal of Molecular Biology. 2003;330:1061-1075.
  59. Gaynor M, Mankin AS. Macrolide antibiotics: Binding site, mechanism of action, resistance. Frontiers in Medicinal Chemistry. 2005;2:21-35.
  60. Nelson ML, Levy SB. 3.25 -Tetracyclines and tetracycline derivatives. Comprehensive biotechnology (second edition). Burlington, American: Academic Press; 2011. p. 269-283.
  61. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiology and Molecular Biology Reviews. 2001;65:232-260.
  62. Pato ML. Tetracycline inhibits propagation of deoxyribonucleic acid replication and alters membrane properties. Antimicrobial Agents and Chemotherapy. 1977;11:318-323.
  63. Lee M-Y, Myeong JS, Park HJ, Han K, et al. Isolation and partial characterization of a cryptic polyene gene cluster in pseudonocardia autotrophica. Journal of Industrial Microbiology and Biotechnology. 2006;33:84-87.
  64. Ellis D. Amphotericin b: Spectrum and resistance. Journal of Antimicrobial Chemotherapy. 2002;49:7-10.
  65. Paquet V, Carreira EM. Significant improvement of antifungal activity of polyene macrolides by bisalkylation of the mycosamine. Organic Letters. 2006;8:1807-1809.